Certain Common Stock of Krystal Biotech, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2021.
May 02, 2021
Share
Certain Common Stock of Krystal Biotech, Inc. are subject to a Lock-Up Agreement Ending on 3-MAY-2021. These Common Stock will be under lockup for 90 days starting from 2-FEB-2021 to 3-MAY-2021.
Details:
Directors and executive officers have entered into lock-up agreements with the representatives prior to the commencement of this offering pursuant to which they have agreed for a period of 90 days, without the prior written consent of the representatives and subject to certain limited exceptions, not to (i) offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any shares of common stock, or any options or warrants to purchase any shares of common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of company's common stock
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patientâs skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
KRYSTAL BIOTECH, INC. 
